Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization - Fan, Wenzhe; Zhu, Bowen; Zheng, Xinlin; Yue, Shufan; Lu, Mingjian; Fan, Huishuang; Qiao, Liangliang; Li, Fuliang; Yuan, Guosheng; Wu, Yanqin; Zou, Xinhua; Wang, Hongyu; et al. (Journal of cancer research and clinical oncology, 2023)
Keywords: Cancer Research; Carcinoma, Hepatocellular - drug therapy; Chemoembolization; Chemoembolization, Therapeutic - adverse effects; China; Disease control; Drug delivery; ethics; fever; hazard ratio; Hematology; Hepatocellular carcinoma; hepatoma; Humans; Hyperbilirubinemia; Inhibitor drugs; Internal Medicine; Liver cancer; Liver Neoplasms - drug therapy; Medicine; Medicine & Public Health; Multivariate analysis; Oncology; Original Article – Clinical Oncology; Original – Clinical Oncology; pain; Patients; Retrospective Studies; Sorafenib; Targeted cancer therapy; Treatment Outcome; Vomiting; α-Fetoprotein; China; Hepatocellular carcinoma; Stage progression; Transarterial chemoembolization; Sorafenib